We are live on ! Find out more
IMGN

Immunogen Inc

Delisted

IMGN was delisted on the 9th of February, 2024.

192 hedge funds and large institutions have $221M invested in Immunogen Inc in 2019 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 63 increasing their positions, 53 reducing their positions, and 43 closing their positions.

New
Increased
Maintained
Reduced
Closed

187% more call options, than puts

Call options by funds: $2.47M | Put options by funds: $860K

19% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 53

9% less funds holding

Funds holding: 212192 (-20)

31% less capital invested

Capital invested by funds: $320M → $221M (-$98.4M)

37% less first-time investments, than exits

New positions opened: 27 | Existing positions closed: 43

Holders
192
Holders Change
-20
Holders Change %
-9.43%
% of All Funds
4.17%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
27
Increased
63
Reduced
53
Closed
43
Calls
$2.47M
Puts
$860K
Net Calls
+$1.61M
Net Calls Change
-$1.11M
Name Holding Trade Value Shares
Change
Change in
Stake
CM
76
Caption Management
Oklahoma
$174K +$186K +78,800 +6,567%
BBI
77
Baxter Bros Inc
Connecticut
$170K +$26K +11,000 +16%
State Board of Administration of Florida Retirement System
78
State Board of Administration of Florida Retirement System
Florida
$168K
Janney Montgomery Scott
79
Janney Montgomery Scott
Pennsylvania
$166K +$348 +147 +0.2%
GC
80
Grace Capital
Massachusetts
$155K +$28.4K +12,000 +20%
Envestnet Asset Management
81
Envestnet Asset Management
Illinois
$154K +$18.4K +7,790 +12%
AQR Capital Management
82
AQR Capital Management
Connecticut
$142K -$251K -106,021 -62%
VOYA Investment Management
83
VOYA Investment Management
Georgia
$130K -$3.23M -1,366,691 -96%
MIM
84
MetLife Investment Management
New Jersey
$130K
ProShare Advisors
85
ProShare Advisors
Maryland
$128K -$17.5K -7,405 -11%
Los Angeles Capital Management
86
Los Angeles Capital Management
California
$123K -$30.2K -12,790 -18%
CSS
87
Cubist Systematic Strategies
Connecticut
$114K -$13.8K -5,826 -10%
PP
88
Paloma Partners
Connecticut
$112K +$122K +51,400 New
MLICM
89
Metropolitan Life Insurance Company (MetLife)
New York
$106K +$17.3K +7,328 +18%
ZIM
90
Zacks Investment Management
Illinois
$95K +$79.2K +33,476 +330%
Squarepoint
91
Squarepoint
New York
$93K -$613K -259,390 -86%
M&T Bank
92
M&T Bank
New York
$87K +$11K +4,649 +13%
Walleye Capital
93
Walleye Capital
New York
$87K +$94.6K +40,000 New
Principal Financial Group
94
Principal Financial Group
Iowa
$82K -$182K -76,941 -67%
BFM
95
Boothbay Fund Management
New York
$78K +$15.9K +6,725 +23%
NFC
96
Northeast Financial Consultants
Connecticut
$74K
LPL Financial
97
LPL Financial
California
$74K +$1.18K +498 +1%
MML Investors Services
98
MML Investors Services
Massachusetts
$64K +$9.54K +4,034 +16%
SI
99
Stephens Inc
Arkansas
$62K -$3.9K -1,647 -5%
Walleye Trading
100
Walleye Trading
New York
$59K +$63.8K +26,979 New

IMGN Hedge Fund Activity: Q2 2019 in Review

192 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Immunogen Inc (IMGN) for Q2 2019, worth a combined $221M — down 31% from $320M a quarter earlier.

Sellers outnumbered buyers: 43 funds closed out of IMGN and 27 opened new positions — a net loss of 16 holders — while 53 trimmed existing stakes and 63 added.

The largest buyer was Morgan Stanley, adding an estimated $5.9M. The largest seller was State Street, cutting an estimated $22.9M.

  • 192 institutional investors held Immunogen Inc (IMGN) as of Q2 2019, down from 212 in Q1 2019.
  • Funds reported $221M of Immunogen Inc stock for Q2 2019, down 31% quarter-over-quarter.
  • 27 funds opened new Immunogen Inc positions in Q2 2019 and 43 closed out, a net change of -16 holders.
  • The largest Immunogen Inc buyer in Q2 2019 was Morgan Stanley, an estimated $5.9M added.
  • The largest Immunogen Inc seller in Q2 2019 was State Street, an estimated $22.9M sold.

Based on aggregated 13F filings for Q2 2019.